National Brain Tumor Society’s (NBTS) chief executive officer David Arons, JD, today released the following statement applauding the inclusion of an ARPA-H program in President Joe Biden’s Fiscal Year 2022 Budget, and urging bipartisan congressional support of medical research funding:
“As a leading proponent of the need for cancer research funding, President Biden has dedicated critical resources toward the advancement of new treatments in his FY 2022 budget. We applaud the administration’s inclusion of an ARPA-H program in the proposed FY2022 budget. NBTS supports strong funding increases to the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA).
Increasing funding for our core medical research agencies is urgently needed for the 700,000 Americans living with a primary brain tumor, the thousands more living with metastatic brain cancer, and their many loved ones.
This funding will spur innovation that will enable the scientific breakthroughs we are so close to realizing, with the potential to change the future of cancer treatment and outcomes, and one day, create cures and improve quality of life.
NBTS encourages Congress to continue its bipartisan commitment and provide a robust increase in funding for medical research and drug development that will not only save the lives of Americans, but will ensure that the United States continues to be a global leader in scientific discovery.
Americans need and deserve a coordinated national strategy dedicated to the fight against cancer and in particular brain tumors, for which incidence and mortality rates have not changed for the better as they have for other cancers. We look forward to working closely with the Biden administration and Congress to implement these programs and maximize benefits for Americans living with brain tumors and their families.”